CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2540 participants.
Also called NCT05931276
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,540 participants
- Registry
-
NCT05931276
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05931276. Randomized; no masking; primary purpose treatment. Start 2024-05-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- Acronym
- BRAVO
- Condition
- End-Stage Kidney Disease
- Condition
- End-Stage Renal Disease
- Intervention (Drug)
- Metoprolol Succinate
- Intervention (Drug)
- Carvedilol
- Lead sponsor
- VA Office of Research and Development
Record details
- Record id
cardio:ct-nct05931276- Content hash
371fd29abde3e58bf16ee454c7e87cbb74290b385a3644f3b1cbce15a670acf4